MAPT and neurodegenerative disease: The ratio of CSF Aβ42/Aβ40 and plasma pTau181 correlates with Aβ-PET and tau-PET findings, respectively, and can discriminate AD dementia from CU controls and non-AD neurodegenerative diseases [9,10,39].